Advanced Cardiac Therapeutics, Inc., a Santa Clara, Calif.-based medical device company focused on developing a next-generation ablation catheter to treat cardiac arrhythmias including atrial fibrillation, raised $45m in equity funding.
The round was led by Ajax Health with participation from existing investor New Enterprise Associates and new investor Questa Capital Management. In conjunction with the funding, Justin Klein, MD, a partner at NEA, and representatives of Ajax and Questa will join ACT’s Board of Directors.
The company will use proceeds from the financing to pursue a global clinical development program and earn regulatory approvals for use of its portfolio of products in Europe and the U.S.
Led by CEO Duke Rohlen, and newly named President and Chief Operating Officer Dr. Philippe Henri Marco, Advanced Cardiac Therapeutics is a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation and other cardiac arrhythmias. The catheter ablation system, which includes the company’s proprietary DiamondTemp™ Catheter, DiamondTemp™ RF Generator, and integrated fluid Irrigation Pump, combines temperature control, contact sensing, and high resolution electrogram recording to treat atrial fibrillation through a minimally invasive approach.